FDA Brief

Warning letters Drugs

FDA warning letter to

Landy International

High riskIssued Jun 12, 2024Posted Jun 18, 2024Center for Drug Evaluation and Research | CDER

FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.

What happened

FDA inspected Landy International’s drug manufacturing facility in Xiamen, China, from December 11 to 14, 2023. Investigators found the company released OTC hand sanitizer batches without testing ethanol identity and strength, failed to test components such as ethanol for methanol and glycerin for diethylene glycol or ethylene glycol contamination, used water from a biofilm-contaminated system, and lacked controls over laboratory computer data. FDA also placed the firm on Import Alert 66-40, which can stop its products from entering the U.S., on May 24, 2024.

What FDA found

  1. Failed to test each finished hand sanitizer batch for identity and strength of ethanol before release.

    21 CFR 211.165(a)
  2. Failed to test each component lot for identity and conformity and failed to establish the reliability of supplier test results, including no methanol test on incoming ethanol and no identity test on glycerin for diethylene glycol or ethylene glycol.

    21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)
  3. Failed to adequately design and control the water system; biofilm, stagnant water, leaks, and pooling water were found, and water from a biofilm-contaminated tank was used to make released drug products.

    21 CFR 211.100(a); see also 21 CFR 211.113(a) and 21 CFR 211.160(b)
  4. Failed to control the gas chromatograph computer system; it lacked an audit trail and individual logins, used a shared password kept in an unsecured drawer, and had deleted files in the recycle bin.

    21 CFR 211.68(b)
  5. FDA warned that some products may be cosmetics and could be adulterated if prepared, packed, or held under insanitary conditions.

    FD&C Act section 601(c)

What FDA wants

FDA asks the company to respond in writing within 15 working days with corrective actions, risk assessments, retained-sample testing, and a data integrity remediation plan. FDA also recommends an independent qualified CGMP consultant and says it may withhold approvals or refuse admission until the firm corrects the violations.

Who should pay attention

  • brands and distributors that buy OTC hand sanitizer from this contract manufacturer
  • retailers selling hand sanitizers or cosmetics made in Xiamen
  • quality teams sourcing ethanol or glycerin for drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk